Abstracts Journal of Thoracic Oncology

Abstracts Journal of Thoracic Oncology
Journal of Thoracic Oncology Volume 4, Issue 9, Pages S5-S968 (September 2009) DOI: /JTO.0b013e3181b9c77e Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure Empiric Approach to Selection of Therapy for NSCLC
Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Map 1 Parties to the WHO FCTC in the South America sub-region6

Map 2 Taxes in the South America sub-region

Map 3 Packaging and labeling regulations in the South America sub-region Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Map 4 Smoke-free environments in the South America sub-region

Map 5 Advertising, promotion and sponsorship bans in the South America sub-region Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Bronchial confocal microendoscopy imaging:
A. Normal elastic fibered network of the basement membrane zone. B. Disorganized basement membrane zone elastic network at the vicinity of a bronchial CIS C. Regular normal bronchial epithelium 660 nm excitation FCFM after topical application of methylene blue (0,1%). D. CIS imaging, FCFM at 660 nm and topical methylene blue. Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 FCFM imaging of normal distal lung and peripheral lung nodule: A. FCFM imaging of normal distal lung B. Interstitial fiber network disorganisation in a peripheral lung adenocarcinoma (488 nm excitation wave length) C. FCFM cellular imaging of a peripheral lung adenocarcinoma (660 nm excitation and topical methylene blue) Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1A Median survival of patients with ERCC1 of > 50 (94.6 months) vs < 50 (35.5 months) (p = 0.01). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1B Median survival of patients with ERCC1 of < 30 (35.5 months), 30 to 100 (62.1 months), and > 100 (94.6 months) (p = 0.03, two-sided log-rank test). (Adapted from Simon et al with permission (3)). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2(A) Overall survival (OS) and progression-free survival (PFS) of 53 patients with advanced non-small-cell lung cancer treated with chemotherapy based on expression of the genes ribonucleotide reductase subunit 1 (RRM1) and excision repair cross-complementing group 1 gene (ERCC1). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2(B) Overall survival (OS) by assigned chemotherapy. DC, docetaxel and carboplatin; GC, gemcitabine and carboplatin; DV, docetaxel and vinorelbine; GD, gemcitabine and docetaxel. Adapted with permission from Simon et al(15). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Journal of Thoracic Oncology 2009 4, S5-S968DOI: (10. 1097/JTO

Figure 1 Examples of dose-efficacy curves for targeted agents and novel therapies Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Cancer stem cell–specific therapeutic approaches.

Figure 1 Overall survival based on EGFR and KRAS status.

Figure 2 Comparison of outcomes by clinical enrichment and EGFR mutation analysis. Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Boxplots of the expression levels ofTS In NSCLC-SCCA. NSCLC-adenoca and CRC are demonstrated. Statistical differences in TS expression levels are displayed in the figure (Mann-Whitney Test). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Boxplots of the expression levels of RRM1 in NSCLC-SCCA and NSCLC-adenoca are demonstrated The statistical significance of íhe RRM1 expression levels of the &vo histological NSCLC types is displayed in trie figure (Mann-Whitney Test pO.001). Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Image 1 Comparison of ABS on axial, coronal, sagittal and tilted planes of HRCT Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Area of Consolidation & Proportion of Consolidation Scattered Plots Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Disease Free Survival (DFS) and Overall Survival (OS).

Figure 1 Increased expression of TRAIL by SAHA

Figure 1 C4.4A expression in bronchial squamous metaplasia

Figure 1 Type 1, widespread leptomeninges metastases (3 of 7)

Figure 2 Type 2, multiple diffuse small nodules (6 of 7)

Patient with squamous cell carcinoma of the lung: Axial, coronal and sagittal 18F-HX4 PET images 120 minutes after injection. Tumour to muscle ratio: 1.77 Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Example of Histogram analysis

Figure 1 SM correlated with the clinical response of MM pts: a decreasing trend in pts with partial response (left) and an increasing trend in pts with progressive disease (right) was present. c1-6: chemo cycle 1-6. Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overall survival

Figure 2 Progression free survival

Figure 2 TNM staging for Sarcomas according to grade and size of tumors Journal of Thoracic Oncology 2009 4, S5-S968DOI: ( /JTO.0b013e3181b9c77e) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Abstracts Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "Abstracts Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback

Log in

Auth with social network:

Abstracts Journal of Thoracic Oncology

Similar presentations

Presentation on theme: "Abstracts Journal of Thoracic Oncology"— Presentation transcript:

Similar presentations

About project

Feedback